dexfenfluramine has been researched along with n-methyl-3,4-methylenedioxyamphetamine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalia, M; Kramer, M; Miller, DB; O'Callaghan, JP | 1 |
| Laverty, R; Russell, BR | 2 |
| Cohen, AF; Gijsman, HJ; Hessing, TJ; Pennings, EJ; Pieters, MS; Schoemaker, RC; van Gerven, JM; Verkes, RJ | 1 |
| Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH | 1 |
1 review(s) available for dexfenfluramine and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Drug-induced fibrotic valvular heart disease.
Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents | 2009 |
1 trial(s) available for dexfenfluramine and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Saccadic peak velocity and EEG as end-points for a serotonergic challenge test.
Topics: Adolescent; Adult; Cross-Over Studies; Dexfenfluramine; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Norfenfluramine; Saccades; Serotonin; Serotonin Receptor Agonists; Substance-Related Disorders | 2002 |
3 other study(ies) available for dexfenfluramine and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Dexfenfluramine; Eating; Fluoxetine; Immunohistochemistry; Male; N-Methyl-3,4-methylenedioxyamphetamine; Prefrontal Cortex; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Sertraline | 2000 |
Correlation between 5-HT content and uptake site density following (S)-MDMA and dexfenfluramine-induced depletion, and with neuroprotection by the glycine site-specific NMDA antagonist ACEA 1021.
Topics: Animals; Animals, Newborn; Brain; Brain Chemistry; Dexfenfluramine; Drug Interactions; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neuroprotective Agents; Paroxetine; Quinoxalines; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Tritium | 2000 |
The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity.
Topics: Animals; Autoradiography; Body Temperature; Brain Chemistry; Carrier Proteins; Chromatography, High Pressure Liquid; Dexfenfluramine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurotoxicity Syndromes; Pyrrolidinones; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Stereoisomerism; Telemetry | 2001 |